GlassScriptPhysician profile
Sriram Naidu
NPI 1184601643
$3,155.68
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,646 · 2020: $351 · 2021: $17.41 · 2022: $141.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $401.97 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $301.55 | 2019-2020 | |
| Akcea Therapeutics, INC. | $276.89 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $259.68 | 2019-2020 | |
| Amgen INC. | $239.92 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.76 | 2019-2020 | |
| Allergan, INC. | $208.74 | 2019 | |
| Arbor Pharmaceuticals, INC. | $203.06 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $200.37 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $163.35 | 2019-2022 | |
| Pfizer INC. | $158.05 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $153.96 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $125.00 | 2019 | |
| Biotronik INC. | $123.73 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $37.13 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $36.11 | 2019 | |
| Irhythm Technologies, INC. | $22.49 | 2022 | |
| Gilead Sciences, INC. | $15.92 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sriram Naidu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.